GeneDx Holdings Corp

GeneDx Holdings Corp maintains a conservative capital structure with a debt-to-equity ratio of 0.16, indicating limited leverage relative to its equity base of $308.2 million. The company holds $105.0 million in cash and equivalents against $48.2 million in long-term debt, resulting in a net cash position that supports its low liquidity risk assessment. With a market capitalization of $1.74 billion and a price-to-book ratio of 5.63, the market values the firm significantly above its tangible book value, reflecting expectations for future growth rather than current asset backing. The enterprise value-to-revenue multiple stands at 3.79, suggesting a premium valuation relative to sales despite current unprofitability.

Profitability metrics indicate the company is currently investing in growth at the expense of near-term earnings, with a net loss of $21.0 million and an operating loss of $13.1 million on revenues of $427.5 million. The return on equity is negative at -25.25%, and return on assets is -14.86%, highlighting the drag from operating losses on the balance sheet. However, the company generates positive operating cash flow of $33.3 million, which exceeds its capital expenditures of $19.0 million, resulting in positive free cash flow that helps sustain operations without immediate external financing. The gross profit of $298.2 million represents a gross margin of approximately 69.7%, demonstrating strong pricing power or low cost of goods sold typical of diagnostic service providers.

Revenue concentration and segment details are not explicitly broken down in the provided financial snapshot, but the company operates within the Health Care Providers & Services industry, suggesting a diversified client base across healthcare providers and laboratories. The geographic exposure is not detailed in the available data, but as a US-listed entity with a primary market in the United States, the majority of revenue is likely derived from domestic operations. The lack of specific segment data limits the ability to assess concentration risk within specific product lines or regions, but the overall revenue base of $427.5 million provides a substantial scale for the business.

Growth trajectory analysis is constrained by the absence of historical period data in the input, preventing a direct calculation of year-over-year revenue or earnings growth trends. However, the current revenue run rate of $427.5 million and the positive operating cash flow suggest a stable operational base. The market's valuation, with an EV/Revenue of 3.79, implies expectations for continued revenue expansion and eventual profitability, despite the current net loss of $21.0 million. The company's ability to generate positive cash flow while investing in growth is a key indicator of its strategic positioning.

Risk assessment indicates low liquidity risk and low dilution risk, with no immediate filing-based flags detected for liquidity or dilution concerns. The company's strong cash position of $105.0 million relative to its long-term debt of $48.2 million further mitigates financial risk. The negative EV/EBITDA of -23.14 reflects the current unprofitability but is less concerning given the positive operating cash flow and low debt levels. The primary risk lies in the company's ability to convert its current revenue growth and cash flow generation into sustainable net income, as indicated by the negative ROE and ROA.

Recent events and analyst sentiment are strongly positive, with a mean price target of $92.89 and a median target of $85.00, significantly above the current market price of $59.35. The mean recommendation of 1.67, with 3 strong buys and 6 buys and no holds, indicates high analyst confidence in the company's future prospects. The high price target of $170.00 suggests a wide range of potential upside, while the low target of $63.00 provides a near-term support level. This bullish sentiment contrasts with the current financial losses, implying that analysts expect a significant turnaround in profitability or continued high growth in revenue and cash flow.

Revenue grew 40% year-over-year to $427.5 million in FY2026, demonstrating strong top-line expansion momentum.

Gross profit surged to $298.2 million in FY2026, indicating significant improvement in core operational profitability.

Net income improved by 59.8% year-over-year, reflecting a substantial reduction in annual losses.

Free cash flow improved by 58.6% year-over-year, signaling better cash generation capabilities.

The company maintains a low debt-to-equity ratio of 0.17, suggesting manageable leverage levels.

The company faces high credit risk according to internal risk flag assessments.

Free cash flow remains negative at -$14.8 million, indicating continued reliance on external funding.

Revenue $102.3M, +17,4% YoY; Operating income −1 307,1% YoY.

• ▍Revenue $102.3M, +17,4% YoY
• ▍Operating income −1 307,1% YoY
• ▍Net income −869,8% YoY
• ▍Free cash flow −802,0% YoY
• ▍Net margin -61.9%

Revenue $121.0M, +26,5% YoY; Operating income −261,6% YoY.

• ▍Revenue $121.0M, +26,5% YoY
• ▍Operating income −261,6% YoY
• ▍Net income −424,9% YoY
• ▍Free cash flow −291,5% YoY
• ▍Net margin -14.6%

Revenue $116.7M, +51,9% YoY; Operating income +58,2% YoY.

• ▍Revenue $116.7M, +51,9% YoY
• ▍Operating income +58,2% YoY
• ▍Net income +8,1% YoY
• ▍Free cash flow −142,1% YoY
• ▍Net margin -6.5%

Revenue $102.7M, +45,6% YoY; Operating income +184,7% YoY.

• ▍Revenue $102.7M, +45,6% YoY
• ▍Operating income +184,7% YoY
• ▍Net income +137,1% YoY
• ▍Free cash flow +157,8% YoY
• ▍Net margin 10.5%

Revenue $87.1M; Operating income -$4.6M.

• ▍Revenue $87.1M
• ▍Operating income -$4.6M
• ▍Net margin -7.5%

Revenue $95.6M; Operating income $8.8M.

• ▍Revenue $95.6M
• ▍Operating income $8.8M
• ▍Net margin 5.7%

Revenue $76.9M; Operating income -$7.8M.

• ▍Revenue $76.9M
• ▍Operating income -$7.8M
• ▍Net margin -10.8%

Revenue $70.5M; Operating income -$10.6M.

• ▍Revenue $70.5M
• ▍Operating income -$10.6M
• ▍Net margin -41.4%

Revenue $427.5M, +40,0% YoY; Operating income +43,7% YoY.

• ▍Revenue $427.5M, +40,0% YoY
• ▍Operating income +43,7% YoY
• ▍Net income +59,8% YoY
• ▍Free cash flow +58,6% YoY
• ▍Net margin -4.9%

Revenue $305.4M, +50,8% YoY; Operating income +87,3% YoY.

• ▍Revenue $305.4M, +50,8% YoY
• ▍Operating income +87,3% YoY
• ▍Net income +70,2% YoY
• ▍Free cash flow +75,8% YoY
• ▍Net margin -17.1%

Revenue $202.6M, −13,7% YoY; Operating income +72,5% YoY.

• ▍Revenue $202.6M, −13,7% YoY
• ▍Operating income +72,5% YoY
• ▍Net income +68,0% YoY
• ▍Free cash flow +70,3% YoY
• ▍Net margin -86.8%

Revenue $234.7M, +10,6% YoY; Operating income −49,5% YoY.

• ▍Revenue $234.7M, +10,6% YoY
• ▍Operating income −49,5% YoY
• ▍Net income −123,7% YoY
• ▍Free cash flow −103,8% YoY
• ▍Net margin -233.9%